Doxycycline in Treatment of Bleeding With Depot Medroxyprogesterone Acetate (DMPA)
NCT ID: NCT01254799
Last Updated: 2011-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
68 participants
INTERVENTIONAL
2008-01-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Women in this arm will receive identical Placebo capsules twice daily for 5 days
Placebo
Placebo capsules twice daily for 5 days
Doxycycline
Women in this arm will receive 100 mg doxycycline capsules twice daily for 5 days
Doxycycline
100 mg Doxycycline capsules twice daily for 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxycycline
100 mg Doxycycline capsules twice daily for 5 days
Placebo
Placebo capsules twice daily for 5 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Accept to participate in the trial after receiving adequate information about the trial including information that she is a part of randomization comprising the possibility of receiving new treatment for bleeding or inactive ingredients.
3. Women's ability to keep an accurate menstrual diary for the study.
Exclusion Criteria
2. Patients with already diagnosed local gynecological abnormality.
3. Women receiving treatment for bleeding within the last one month.
20 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Omar Mamdouh Shaaban
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Omar Mamdouh Shaaban
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hany Abdel-Aleem, MD
Role: PRINCIPAL_INVESTIGATOR
Assiut University
Omar M Shaaban, MD
Role: STUDY_DIRECTOR
Assiut University
Mahmoud Abdel=Aleem, MD
Role: STUDY_CHAIR
Assiut University
Gehian N Fetih, PH.D
Role: STUDY_CHAIR
Faculty of Pharmacy, Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine
Asyut, Asyut Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA, Fetih GN. Doxycycline in the treatment of bleeding with DMPA: a double-blinded randomized controlled trial. Contraception. 2012 Sep;86(3):224-30. doi: 10.1016/j.contraception.2012.01.003. Epub 2012 Feb 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DOX-DMPA
Identifier Type: -
Identifier Source: org_study_id